The Michael J. Fox Foundation continually strives to communicate our scientific progress -- at meetings, as well as through peer-reviewed scientific publications.
February 11, 2011
World Pharma Conference - Philadelphia
Progress in Parkinson's disease (PD) research and therapeutic development is hindered by the availability of reagents including quality antibodies, robust assays and viral vectors encoding target genes of interest. The limitations are a result of technical hurdles, production and distribution costs, as well as licensing restrictions that prohibit free distribution and inhibit further scientific progress. We hypothesize that directly sponso...Read More